New York State locations receiving monoclonal antibody treatments were added to the Department of Health and Human Services (HHS) treatment locator on its public data hub today. Launched earlier this month with optional participation on a state-by-state basis, the treatment locator was expanded by HHS to include all sites nationally. The treatment locator is a tool that allows users to enter their location and find nearby locations where the monoclonal antibodies bamlanivimab and imdevimab/casirivimab have been shipped.
In November, the US Food and Drug Administration issued emergency use authorizations for bamlanivimab and imdevimab/casirivimab. Both therapeutics are used to treat mild or moderate COVID-19 in high-risk non-hospitalized patients. Hospitals in New York began receiving allocations of monoclonal antibodies in early November. Since then, close to 30,000 doses of the monoclonal antibody therapies bamlanivimab and imdevimab/casirivimab have been distributed to hospitals, with recent HHS data showing approximately 60% use in New York State. GNYHA is proud of the work our members are doing to ensure patient access to these important therapies and applauds HHS’s efforts to educate the public on monoclonal antibodies.
Please contact Zeynep Sumer King with questions about COVID-19 and Amy Chin with questions about monoclonal antibodies.
If you are a patient with questions about monoclonal antibodies, please see this website for more information on locations offering the treatment.